The Purpose of this trial is to investigate the efficacy and safety of Daesiho-tang and Taeeumjowi-tang on Korean obese Women with metabolic syndrome Risk factors
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
120
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Gachon University Gil Oriental Medical Hospital
Incheon, South Korea
Changes from baseline in body weight
Time frame: baseline, 12 weeks
Changes from baseline in body fat percentage
Time frame: baseline, 4,8,12,16 weeks
Changes from baseline in fat mass
Time frame: baseline, 4,8,12,16 weeks
Changes from baseline in Waist circumference
Time frame: baseline, 4,8,12,16 weeks
Changes from baseline in Waist/hip ratio
Time frame: baseline, 4,8,12,16 weeks
Changes from baseline in Body mass index
Time frame: baseline, 4,8,12,16 weeks
Changes from baseline in Lipid profile
Time frame: Screening visit, 12 weeks
Changes from baseline in C-reactive protein (CRP)
Time frame: Screening visit, 12 weeks
Changes from baseline in blood glucose
Time frame: Screening visit, 12 weeks
Changes from baseline in abdominal visceral fat area
Time frame: baseline, 12 weeks
Korean Obesity-related Quality of Life (QoL) scale
Time frame: baseline, 12 weeks
Korean version of Eating Attitudes Test-26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: baseline, 12 weeks